Rizatriptan
rizatriptan benzoate · Brand: Maxalt, Maxalt-MLT
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Acute migraine with or without aura | Adults (≥18 years) | Acute abortive | FDA Approved |
| Acute migraine with or without aura | Pediatric (6–17 years) | Acute abortive (weight-based dosing) | FDA Approved |
Rizatriptan was among the earliest second-generation triptans approved by the FDA (1998) and is distinguished by its rapid onset of action, with peak plasma concentrations reached approximately 1 hour after oral dosing. It is available as both a conventional tablet and an orally disintegrating tablet (Maxalt-MLT), offering convenience for patients with nausea-associated migraine. Rizatriptan is not indicated for migraine prophylaxis or for the treatment of cluster headache, and should not be used in hemiplegic or basilar migraine.
Menstrual migraine (short-term prophylaxis): Small trials suggest rizatriptan 10 mg taken at migraine onset during the perimenstrual window is effective; evidence quality is moderate.
Migraine in children <6 years: Not FDA-approved for this age group; limited data from open-label studies; evidence quality is low.
Dosing
Adult Dosing by Clinical Scenario
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Migraine — first-line oral treatment | 10 mg PO | 10 mg PO | 30 mg/24 h | May repeat ≥2 h after first dose if headache returns 10 mg more effective than 5 mg but more side effects |
| Migraine — dose-sensitive or triptan-naive patients | 5 mg PO | 5–10 mg PO | 30 mg/24 h | Consider starting at 5 mg if prior triptan side effects Step up to 10 mg if 5 mg insufficient |
| Migraine — nausea prominent (ODT preferred) | 10 mg ODT | 10 mg ODT | 30 mg/24 h | Place on tongue, dissolves in saliva; no water needed Similar bioavailability to tablet; Tmax slightly delayed |
| Migraine — co-prescribed with propranolol | 5 mg PO | 5 mg PO | 15 mg/24 h | Propranolol increases rizatriptan AUC by 70% Do NOT use 10 mg dose with propranolol |
Pediatric and Special Population Adjustments
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Pediatric 6–17 years, <40 kg | 5 mg PO | 5 mg PO | 5 mg/24 h | Single dose only; safety of multiple doses not established Do NOT use if also taking propranolol |
| Pediatric 6–17 years, ≥40 kg | 10 mg PO | 10 mg PO | 10 mg/24 h | Single dose only If on propranolol: 5 mg single dose only |
| Elderly patients | 5 mg PO | 5–10 mg PO | 30 mg/24 h | PK similar to younger adults; start low due to CV risk Cardiovascular evaluation before first dose recommended |
Rizatriptan 10 mg achieves peak plasma concentration in approximately 1 hour — the fastest Tmax among oral triptans. In the Ferrari meta-analysis of 53 triptan trials, rizatriptan 10 mg had the lowest NNT for 2-hour pain-free response among oral formulations. Unlike sumatriptan, rizatriptan absorption is not affected by migraine-associated gastric stasis, making it a particularly reliable choice for patients who report delayed or inconsistent response to other oral triptans.
Pharmacology
Mechanism of Action
Rizatriptan is a potent and selective agonist at serotonin 5-HT1B and 5-HT1D receptors. Its anti-migraine action involves two complementary pathways. Stimulation of 5-HT1B receptors on meningeal blood vessels produces selective cranial vasoconstriction, reversing the vasodilation that contributes to migraine pain. Simultaneously, activation of 5-HT1D receptors on trigeminal nerve terminals inhibits the release of pro-inflammatory neuropeptides such as CGRP and substance P, dampening neurogenic inflammation and pain transmission through the trigeminovascular system. These dual actions interrupt the migraine cascade and provide rapid relief of headache, photophobia, phonophobia, and nausea.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | ~90% absorbed; oral bioavailability ~45% (first-pass effect); Tmax ~1–1.5 h (tablet), ~1.6–2.5 h (ODT) | Fastest Tmax among oral triptans; absorption not impaired by migraine-associated gastric stasis; food delays but does not reduce absorption |
| Distribution | Vd ~140 L (males), ~110 L (females); protein binding 14% | Wide distribution; low protein binding makes displacement interactions unlikely; AUC ~30% higher in females |
| Metabolism | Primarily MAO-A to inactive indole acetic acid; minor active metabolite (N-monodesmethyl-rizatriptan, <1% in urine); not a significant CYP substrate | MAO-A inhibitors contraindicated (moclobemide increased AUC by 119%); propranolol increases AUC by 70% via MAO-A pathway; CYP inhibitors do not affect levels |
| Elimination | t½ 2–3 h; 82% urinary (14% unchanged, 51% as IAA metabolite); plasma clearance ~1000–1500 mL/min (males) | Short half-life means headache recurrence is possible; no dose adjustment needed in renal impairment; renal clearance involves active tubular secretion |
Side Effects
Adverse reaction data reflect controlled clinical trials in over 3,700 adult patients who received single or multiple doses of rizatriptan. Incidence rates are from the FDA prescribing information. The most common adverse reactions (≥5% and greater than placebo) are asthenia/fatigue, somnolence, pain/pressure sensation, and dizziness, and appear to be dose-related.
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Neurological events (composite) | 20% (vs 11% placebo) | Includes dizziness, somnolence, headache; dose-related |
| Digestive events (composite) | 13% (vs 8% placebo) | Includes nausea and dry mouth; may overlap with migraine symptoms |
| Adverse Effect | 5 mg / 10 mg / Placebo | Clinical Note |
|---|---|---|
| Dizziness | 4% / 9% / 5% | Marked dose-response; advise against driving after dosing |
| Somnolence | 4% / 8% / 4% | Dose-related; usually transient |
| Asthenia / fatigue | 4% / 7% / 2% | Most common reason patients report feeling unwell after dosing |
| Pain and pressure sensations (all sites) | 6% / 9% / 3% | Includes chest, neck, throat, jaw; usually non-cardiac |
| Nausea | 4% / 6% / 4% | Difficult to distinguish from migraine-associated nausea |
| Atypical sensations / paresthesia | 3–4% / 4–5% / <2–4% | Tingling, warm/cold sensations; brief and self-limiting |
| Chest pain / tightness / pressure | <2% / 3% / 1% | Non-ischemic in most patients; evaluate if CV risk factors present |
| Dry mouth | 3% / 3% / 1% | Mild; resolves spontaneously |
| Neck/throat/jaw tightness | <2% / 2% / 1% | Pressure sensation; typically non-cardiac |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Myocardial ischemia / infarction | Very rare | Within hours of dose | Discontinue permanently; emergency cardiac care |
| Coronary vasospasm (Prinzmetal-type) | Very rare | Minutes to hours | Discontinue permanently; cardiac monitoring |
| Cardiac arrhythmias (VT/VF) | Very rare | Within hours | Emergency resuscitation; permanent discontinuation |
| Cerebrovascular events (stroke, hemorrhage) | Very rare | Variable | Discontinue immediately; neurological assessment |
| Serotonin syndrome | Rare | Minutes to hours (with serotonergic co-administration) | Discontinue all serotonergic agents; supportive care |
| Anaphylaxis / angioedema / toxic epidermal necrolysis | Very rare | Any time | Emergency treatment; permanent contraindication |
| Peripheral vasospasm (GI ischemia, Raynaud syndrome) | Very rare | Hours post-dose | Discontinue; rule out vasospasm before retreatment |
| Seizures | Very rare (postmarketing) | Variable | Discontinue; evaluate seizure threshold |
| Medication overuse headache | Increases with ≥10 days/month use | Weeks to months | Withdrawal and preventive therapy transition |
| Reason for Discontinuation | Incidence | Context |
|---|---|---|
| Headache recurrence | ~30–40% of attacks | Due to short half-life (2–3 h); second dose usually effective |
| Somnolence / fatigue | Dose-related | More pronounced with 10 mg; consider 5 mg if problematic |
| Chest/pressure symptoms | Low (<3% at 10 mg) | Usually non-cardiac; proactive counselling reduces discontinuation |
Somnolence is the most clinically impactful side effect of rizatriptan, affecting 8% of patients at the 10 mg dose (vs 4% placebo). It is dose-related and typically peaks within 1–2 hours of dosing. Patients should be advised to avoid driving or operating heavy machinery until they understand their response. For patients who find 10 mg sedating, the 5 mg dose offers a meaningful reduction in somnolence (4%) with some trade-off in efficacy.
Drug Interactions
Rizatriptan is metabolized primarily by MAO-A and is not a significant substrate for cytochrome P450 enzymes. It is a weak competitive inhibitor of CYP2D6 only at concentrations far above therapeutic levels. The clinically important interactions center on MAO-A-mediated metabolism and serotonergic pharmacology.
Monitoring
- Cardiovascular AssessmentBefore first dose
RoutinePerform CV evaluation in triptan-naive patients with multiple risk factors. Consider first dose in medically supervised setting with ECG if high-risk. - Blood PressureEach clinical visit
RoutineMonitor for hypertension. Slight increases (~2–3 mmHg) observed at maximal doses. Contraindicated in uncontrolled hypertension. - Headache FrequencyMonthly diary
RoutineTrack acute medication use days. Using triptans ≥10 days/month risks medication overuse headache. Safety of treating >4 headaches/month not established. - Serotonin SyndromeEach use with serotonergic drugs
Trigger-basedWatch for agitation, hyperthermia, hyperreflexia, clonus, tremor when co-administered with SSRIs, SNRIs, TCAs, or MAO inhibitors. - Cardiac SymptomsAny new symptom
Trigger-basedEvaluate chest pain, palpitations, or dyspnea for cardiac ischemia before continued use. Most symptoms are non-cardiac. - Periodic CV EvaluationPeriodically
RoutineFor intermittent long-term users with cardiovascular risk factors, periodic cardiovascular re-evaluation is recommended.
Contraindications & Cautions
Absolute Contraindications
- Ischemic coronary artery disease or coronary artery vasospasm (including Prinzmetal angina)
- History of stroke or TIA
- Peripheral vascular disease
- Ischemic bowel disease
- Uncontrolled hypertension
- Hemiplegic or basilar migraine
- Use of another triptan or ergotamine within 24 hours
- Concurrent or recent MAO-A inhibitor use (within 2 weeks)
- Known hypersensitivity to rizatriptan (anaphylaxis, angioedema, toxic epidermal necrolysis reported)
Relative Contraindications (Specialist Input Recommended)
- Multiple cardiovascular risk factors (diabetes, smoking, obesity, strong family CAD history) — requires CV evaluation before first dose
- Controlled hypertension — transient BP elevations may occur
Use with Caution
- Concurrent SSRI/SNRI/TCA therapy — serotonin syndrome risk
- Concurrent propranolol — must reduce rizatriptan dose to 5 mg
- Pregnancy — animal data suggest fetal harm; no clear teratogenic signal in human registry, but data limited
- Phenylketonuria — ODT formulation contains phenylalanine
- High-frequency use (≥10 days/month) — medication overuse headache risk
Serious cardiac events, including myocardial infarction, have occurred following 5-HT1 agonist use. Some events have occurred in patients without known cardiovascular disease. Perform cardiovascular evaluation in patients with multiple risk factors before administering rizatriptan. Consider first dose in a medically supervised setting with post-dose ECG in higher-risk patients.
Patient Counselling
Purpose of Therapy
Rizatriptan is a rescue medication designed to stop a migraine attack once it has started. It works best when taken as early as possible after headache onset. It does not prevent future migraines and should not be taken daily.
How to Take
Swallow the standard tablet whole with water. For the orally disintegrating tablet (ODT), peel open the blister pack with dry hands, place the tablet on the tongue and let it dissolve — it will be swallowed with saliva without water. The medication can be taken with or without food. If the headache returns after initial relief, a second dose can be taken at least 2 hours later. Do not take more than 30 mg in 24 hours. If you take propranolol, use only 5 mg per dose.
Sources
- Rizatriptan Benzoate Tablets — Full Prescribing Information. Revised October 2025. drugs.com/pro/rizatriptan-tabletsCurrent FDA-approved PI for rizatriptan tablets; primary source for dosing, adverse reactions, contraindications, and propranolol interaction data.
- MAXALT / MAXALT-MLT (rizatriptan benzoate) — Full Prescribing Information. Merck & Co. FDA Label (PDF)Brand-name PI with detailed PK parameters, clinical trial efficacy data, and pediatric dosing information.
- Visser WH, Terwindt GM, Reines SA, et al. Rizatriptan vs sumatriptan in the acute treatment of migraine: a placebo-controlled dose-ranging study. Arch Neurol. 1996;53(11):1132-1137. doi:10.1001/archneur.1996.00550110082014Early head-to-head trial establishing rizatriptan’s dose-response relationship and comparative efficacy versus sumatriptan.
- Goldstein J, Ryan R, Jiang K, et al. Crossover comparison of rizatriptan 5 mg and 10 mg versus sumatriptan 25 mg and 50 mg in migraine. Headache. 1998;38(10):737-747. doi:10.1046/j.1526-4610.1998.3810737.xCrossover RCT demonstrating rizatriptan 10 mg superiority over sumatriptan 25 mg and 50 mg for 2-hour pain-free response.
- Ho TW, Pearlman E, Lewis D, et al. Efficacy and tolerability of rizatriptan in pediatric migraineurs: results from a randomized, double-blind, placebo-controlled trial using a novel adaptive enrichment design. Cephalalgia. 2012;32(10):750-765. doi:10.1177/0333102412451358Pivotal trial supporting FDA approval of rizatriptan in pediatric patients aged 6–17 years using weight-based dosing.
- Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the American Headache Society evidence assessment of migraine pharmacotherapies. Headache. 2015;55(1):3-20. doi:10.1111/head.12499AHS evidence assessment establishing Level A evidence for rizatriptan in acute migraine treatment.
- Ferrari MD, Goadsby PJ, Roon KI, Lipton RB. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia. 2002;22(8):633-658. doi:10.1046/j.1468-2982.2002.00404.xDefinitive meta-analysis of all triptans showing rizatriptan 10 mg with the lowest NNT for 2-hour pain-free response among oral formulations.
- Hargreaves RJ. Pharmacology and potential mechanisms of action of rizatriptan. Cephalalgia. 2000;20(Suppl 1):2-9. doi:10.1046/j.1468-2982.2000.020s1002.xComprehensive review of rizatriptan’s pharmacology, comparing absorption kinetics and CNS penetration across triptans.
- Goadsby PJ, Lipton RB, Ferrari MD. Migraine — current understanding and treatment. N Engl J Med. 2002;346(4):257-270. doi:10.1056/NEJMra010917Landmark review of migraine pathophysiology and the mechanism by which triptans inhibit CGRP release from trigeminal nerves.
- Vyas KP, Halpin RA, Geer LA, et al. Disposition and pharmacokinetics of the antimigraine drug rizatriptan in humans. Drug Metab Dispos. 2000;28(1):89-95. PubMed: 10611145Definitive human PK study establishing rizatriptan’s bioavailability (47%), MAO-A metabolism, renal clearance, and metabolite profiles.
- Goldberg MR, Sciberras D, De Smet M, et al. Influence of beta-adrenoceptor antagonists on the pharmacokinetics of rizatriptan in healthy subjects: a randomized, crossover study. Br J Clin Pharmacol. 2001;52(1):69-76. doi:10.1046/j.0306-5251.2001.01420.xKey study quantifying the 70% AUC increase with propranolol co-administration and confirming no interaction with nadolol.
- Wellington K, Plosker GL. Rizatriptan: an update of its use in the management of migraine. Drugs. 2002;62(10):1539-1574. doi:10.2165/00003495-200262100-00007Comprehensive drug review covering clinical pharmacology, efficacy across multiple trials, and tolerability profile of rizatriptan.
- Mannix LK, Savani N, Engbring M, et al. Efficacy and tolerability of rizatriptan for the treatment of migraine in pediatric and adolescent patients. Curr Med Res Opin. 2006;22(10):1947-1955. doi:10.1185/030079906X132497Early pediatric efficacy and safety data supporting weight-based dosing in younger migraine patients.